
  
    
      
        Introduction_NNP
        This_DT paper_NN was_VBD presented_VBN at_IN the_DT 10_CD th_NN European_NNP Congress_NNP
        of_IN Clinical_NNP Microbiology_NNP and_CC Infectious_NNP Diseases_NNP (_( 28_CD -_: 31_CD May_NNP
        2000_CD ,_, Stockholm_NNP ,_, Sweden_NNP )_) ._.
        Sepsis_NNP can_MD be_VB defined_VBN as_IN a_DT systemic_JJ response_NN to_TO
        infection_NN [_NN 1_CD ]_NN ._. The_DT incidence_NN of_IN sepsis_NN worldwide_NN is_VBZ on_IN the_DT
        increase_NN ._. Sepsis_NNP and_CC its_PRP$ sequels_NNS are_VBP the_DT leading_VBG causes_NNS of_IN
        death_NN in_IN intensive_JJ care_NN units_NNS ._. Mortality_NNP rates_NNS are_VBP higher_JJR
        for_IN patients_NNS with_IN pre-existing_JJ disease_NN ,_, medical_JJ conditions_NNS ,_,
        care_NN in_IN the_DT intensive_JJ care_NN unit_NN ,_, and_CC multiple_JJ organ_NN failure_NN
        [_NN 2_CD ,_, 3_CD ]_NN ._. Despite_IN steady_JJ improvements_NNS in_IN antibiotic_JJ therapy_NN
        and_CC intensive_JJ care_NN management_NN during_IN the_DT past_JJ decade_NN ,_,
        mortality_NN has_VBZ remained_VBN close_RB to_TO 50_CD %_NN ._. This_DT high_JJ mortality_NN
        rate_NN has_VBZ continued_VBN to_TO stimulate_VB interest_NN in_IN pharmacological_JJ
        agents_NNS that_WDT might_MD reduce_VB morbidity_NN and_CC mortality_NN [_NN 4_CD ,_, 5_CD ,_, 6_CD ,_,
        7_CD ]_NN ._.
        Steroid_NNP therapy_NN in_IN patients_NNS with_IN sepsis_NN is_VBZ still_RB
        controversial_JJ ._. In_IN the_DT 1960_CD s_VBZ ,_, stress_NN doses_NNS of_IN hydrocortisone_NN
        for_IN the_DT treatment_NN of_IN sepsis_NN were_VBD investigated_VBN ,_, but_CC no_DT
        advantages_NNS could_MD be_VB shown_VBN in_IN a_DT double-blind_JJ multicenter_NN
        study_NN [_NN 8_CD ]_NN ._. This_DT led_VBN to_TO the_DT discontinuation_NN of_IN steroid_NN
        replacement_NN therapy_NN for_IN sepsis_NN ._. In_IN the_DT 1970_CD s_VBZ ,_, therapy_NN with_IN
        pharmacological_JJ doses_NNS of_IN glucocorticoids_NNS was_VBD widely_RB used_VBN in_IN
        patients_NNS with_IN sepsis_NN and_CC septic_JJ shock_NN ._. The_DT most_RBS compelling_JJ
        evidence_NN in_IN favor_NN of_IN corticosteroid_NN treatment_NN was_VBD reported_VBN
        by_IN Schumer_NNP [_NN 9_CD ]_NN in_IN his_PRP$ prospective_JJ randomized_JJ study_NN of_IN
        steroid_NN administration_NN to_TO patients_NNS with_IN septic_JJ shock_NN ._. These_DT
        data_NNS indicate_VBP that_DT methylprednisolone_NN (_( 30_CD mg_NN /_NN kg_NN )_) or_CC
        dexamethasone_NN (_( 3_CD mg_NN /_NN kg_NN )_) reduced_VBD the_DT mortality_NN rate_NN from_IN
        38_CD ._. 4_LS %_NN to_TO 10_CD ._. 5_LS %_NN ._. However_RB ,_, later_RB in_IN the_DT mid-_NN 1980_CD s_VBZ ,_,
        pharmacological_JJ doses_NNS of_IN glucocorticoids_NNS for_IN the_DT treatment_NN
        of_IN sepsis_NN were_VBD investigated_VBN extensively_RB until_IN several_JJ
        clinical_JJ trials_NNS gave_VBD negative_JJ results_NNS [_NN 10_CD ,_, 11_CD ,_, 12_CD ]_NN ._.
        Moreover_RB ,_, there_EX is_VBZ some_DT evidence_NN that_IN the_DT use_NN of_IN high-dose_JJ
        glucocorticoids_NNS in_IN sepsis_NN might_MD be_VB harmful_JJ [_NN 11_CD ]_NN ._.
        Many_JJ studies_NNS have_VBP demonstrated_VBN that_WDT elevated_JJ cortisol_NN
        levels_NNS in_IN sepsis_NN and_CC the_DT degree_NN of_IN elevation_NN are_VBP related_VBN to_TO
        the_DT severity_NN of_IN illness_NN [_NN 13_CD ]_NN ._. Basal_NNP and_CC corticotropin_NN
        (_( ACTH_NNP )_) -_: stimulated_VBN cortisol_NN levels_NNS correlate_VBP with_IN the_DT
        severity_NN of_IN illness_NN ,_, and_CC very_RB high_JJ cortisol_NN levels_NNS often_RB
        signify_VB a_DT poor_JJ prognosis_NN [_NN 14_CD ]_NN ._. In_IN sepsis_NN ,_, the_DT
        hypothalamic-pituitary-adrenal_JJ axis_NNS is_VBZ activated_VBN through_IN
        systemic_JJ and_CC neural_NN pathways_NNS ._. Circulating_NNP cytokines_NNS such_JJ as_IN
        tumor_NN necrosis_NNS factor_NN Î±_NN ,_, interleukin-_NN 1_CD and_CC interleukin-_NN 6_CD
        activate_VBP the_DT hypothalamic-pituitary-adrenal_JJ axis_NNS
        independently_RB and_CC ,_, when_WRB combined_VBN ,_, have_VBP synergistic_JJ effects_NNS
        [_NN 15_CD ]_NN ._.
        Sepsis_NNP can_MD also_RB cause_VB adrenal_NN insufficiency_NN (_( AI_NNP )_) ,_, which_WDT
        is_VBZ associated_VBN with_IN increased_VBN mortality_NN [_NN 16_CD ]_NN ._. In_IN recent_JJ
        years_NNS ,_, several_JJ authors_NNS have_VBP proposed_VBN a_DT syndrome_NN of_IN occult_NN
        AI_NNP in_IN septic_JJ shock_NN in_IN the_DT presence_NN of_IN normal_JJ or_CC even_RB
        elevated_VBD serum_NN cortisol_NN concentrations_NNS ._. This_DT hypothesis_NNS is_VBZ
        based_VBN on_IN many_JJ studies_NNS investigating_VBG the_DT adrenocortical_JJ
        response_NN of_IN patients_NNS with_IN septic_JJ shock_NN to_TO 0_CD ._. 25_CD mg_NN of_IN ACTH_NNP ._.
        Up_IN to_TO 28_CD %_NN of_IN seriously_RB ill_JJ patients_NNS have_VBP been_VBN suggested_VBN to_TO
        have_VB occult_NN or_CC unrecognized_JJ AI_NNP [_NN 14_CD ]_NN ._. The_DT prevalence_NN of_IN
        occult_NN AI_NNP (_( a_DT cortisol_NN increment_NN after_IN a_DT short_JJ ACTH_NNP test_NN of_IN
        less_JJR than_IN 9_CD mg_NN /_NN dl_NN )_) in_IN severe_JJ sepsis_NN was_VBD estimated_VBN at_IN about_IN
        50_CD %_NN and_CC the_DT 28_CD -_: day_NN mortality_NN rate_NN at_IN about_IN 75_CD %_NN [_NN 17_CD ]_NN ._. A_DT few_JJ
        studies_NNS have_VBP indicated_VBN that_IN stress_NN doses_NNS of_IN hydrocortisone_NN
        improve_VB hemody-namics_JJ in_IN patients_NNS with_IN hyperdynamic_JJ septic_JJ
        shock_NN ,_, which_WDT is_VBZ unresponsive_JJ to_TO conventional_JJ therapy_NN [_NN 18_CD ,_,
        19_CD ]_NN ._. However_RB ,_, the_DT use_NN of_IN a_DT physiological_JJ dose_NN of_IN steroid_NN in_IN
        patients_NNS with_IN sepsis_NN ,_, severe_JJ sepsis_NN ,_, and_CC septic_JJ shock_NN has_VBZ
        not_RB yet_RB been_VBN completely_RB evaluated_VBN ._. We_PRP therefore_RB performed_VBD a_DT
        placebo-controlled_JJ ,_, randomized_JJ ,_, double-blind_JJ ,_, single-center_JJ
        study_NN ._.
        The_DT aim_NN of_IN this_DT study_NN was_VBD to_TO assess_VB basal_NN cortisol_NN
        concentrations_NNS and_CC the_DT cortisol_NN response_NN to_TO ACTH_NNP
        stimulation_NN as_RB well_RB as_IN their_PRP$ prognostic_JJ importance_NN ,_, and_CC
        also_RB to_TO determine_VB the_DT effects_NNS of_IN the_DT physiological-dose_JJ
        steroid_NN therapy_NN on_IN mortality_NN in_IN patients_NNS with_IN sepsis_NN ._.
      
      
        Methods_NNP
        
          Study_NN design_NN
          The_DT study_NN protocol_NN was_VBD approved_VBN by_IN the_DT Institutional_NNP
          Review_NNP Board_NNP of_IN Erciyes_NNP University_NNP and_CC informed_VBN consent_NN
          was_VBD obtained_VBN from_IN the_DT patients_NNS '_POS relatives_NNS ._. This_DT
          placebo-controlled_JJ ,_, randomized_JJ ,_, double-blind_JJ ,_,
          single-center_JJ study_NN was_VBD performed_VBN at_IN the_DT Department_NNP of_IN
          Medical_NNP Intensive_NNP Care_NNP Unit_NNP and_CC the_DT Department_NNP of_IN
          Infectious_NNP Diseases_NNP of_IN Erciyes_NNP University_NNP Medical_NNP School_NNP
          during_IN a_DT 2_CD -_: year_NN period_NN (_( from_IN May_NNP 1997_CD to_TO April_NNP 1999_CD )_) ._.
        
        
          Patient_NNP selection_NN
          Patients_NNS over_IN 17_CD years_NNS old_JJ and_CC diagnosed_VBN with_IN sepsis_NN
          were_VBD included_VBN consecutively_RB in_IN the_DT study_NN ._. The_DT diagnosis_NN
          of_IN sepsis_NN was_VBD based_VBN on_IN the_DT definition_NN of_IN the_DT American_NNP
          College_NNP of_IN Chest_NNP Physicians_NNPS /_NN Society_NNP of_IN Critical_JJ Care_NNP
          Medicine_NNP Consensus_NNP Conference_NNP Report_NNP [_NN 1_CD ]_NN ._. The_DT severity_NN
          of_IN illness_NN was_VBD classified_VBN according_VBG to_TO this_DT definition_NN
          (_( Table_NNP 1_LS )_) ._.
          Criteria_NNP for_IN exclusion_NN from_IN the_DT study_NN were_VBD as_IN follows_VBZ :_:
          already_RB known_VBN pre-existing_JJ adrenal_NN disease_NN or_CC
          adrenalectomy_NN ,_, known_VBN malignancies_NNS ,_, tuberculosis_NNS that_WDT
          might_MD have_VB involved_VBN the_DT adrenal_NN gland_NN ,_, and_CC administration_NN
          of_IN steroids_NNS within_IN the_DT 3_CD months_NNS before_IN the_DT admission_NN ._. In_IN
          addition_NN ,_, patients_NNS with_IN burns_NNS ,_, hemorrhagic_JJ shock_NN or_CC those_DT
          who_WP had_VBD suffered_VBN myocar-dial_JJ infarction_NN were_VBD not_RB
          included_VBN ._.
        
        
          Treatment_NNP protocol_NN
          Patients_NNS enrolled_VBD in_IN the_DT study_NN were_VBD treated_VBN with_IN
          standard_JJ therapy_NN used_VBN in_IN the_DT treatment_NN of_IN sepsis_NN and_CC
          septic_JJ shock_NN ._. This_DT therapy_NN could_MD include_VB the_DT following_VBG :_:
          administration_NN of_IN antibiotics_NNS ,_, fluid_JJ replacement_NN ,_,
          vasoactive_JJ drugs_NNS ,_, mechanical_JJ ventila-tory_JJ support_NN ,_, and_CC
          any_DT other_JJ form_NN of_IN supportive_JJ therapy_NN deemed_VBD necessary_JJ by_IN
          the_DT primary_JJ physicians_NNS ._. Soon_RB after_IN the_DT presumptive_JJ
          diagnosis_NN of_IN severe_JJ sepsis_NN ,_, initial_JJ laboratory_NN specimens_NNS
          were_VBD obtained_VBN and_CC within_IN 2_CD hours_NNS the_DT patients_NNS were_VBD
          randomized_JJ to_TO treatment_NN with_IN prednisolone_NN or_CC placebo_NN
          groups_NNS ._. The_DT treatment_NN groups_NNS were_VBD determined_VBN by_IN a_DT
          computer-generated_JJ randomization_NN procedure_NN ._. The_DT steroid_NN
          therapy_NN group_NN received_VBD prednisolone_NN at_IN a_DT physiological_JJ
          dose_NN ._. Prednisolone_NNP was_VBD given_VBN intravenously_RB at_IN 06_CD ._. 00_CD (_( 5_CD
          mg_NN )_) and_CC 18_CD ._. 00_CD (_( 2_CD ._. 5_LS mg_NN )_) for_IN 10_CD days_NNS ._. The_DT standard_JJ therapy_NN
          group_NN received_VBD a_DT placebo_NN infusion_NN containing_VBG
          physiological_JJ saline_NN solution_NN in_IN an_DT identical_JJ manner_NN ._.
          Patients_NNS and_CC their_PRP$ primary_JJ physicians_NNS were_VBD blinded_JJ as_IN to_TO
          which_WDT therapy_NN was_VBD administered_VBN ._.
        
        
          Data_NNP collection_NN
          An_DT ACTH_NNP stimulation_NN test_NN was_VBD performed_VBN with_IN 250_CD g_SYM of_IN
          tetracosactrin_NN (_( synacthene_NN ;_: Ciba_NNP Geigy_NNP ,_, Germany_NNP )_) given_VBN
          intravenously_RB ._. Blood_NNP samples_NNS were_VBD taken_VBN immediately_RB
          before_IN the_DT test_NN and_CC at_IN 30_CD and_CC 60_CD minutes_NNS afterwards_RB ._.
          After_IN centrifugation_NN ,_, plasma_NN samples_NNS were_VBD stored_VBN at_IN -_: 20_CD Â°_NN C_NNP
          until_IN assayed_JJ ._. ACTH_NNP stimulation_NN test_NN was_VBD repeated_VBN on_IN the_DT
          14_CD th_NN day_NN in_IN the_DT patients_NNS who_WP survived_VBD ._. Plasma_NNP cortisol_NN
          concentrations_NNS were_VBD determined_VBN by_IN radioimmunoassay_NN with_IN a_DT
          commercially_RB available_JJ kit_NN (_( ICN_NNP Biomedicals_NNP ,_, Inc_NNP ,_, Costa_NNP
          Mesa_NNP ,_, California_NNP ,_, USA_NNP )_) ._. Intra-assay_NNP coefficients_NNS of_IN
          variation_NN were_VBD for_IN control_NN A_DT 7_CD ._. 0_CD %_NN ,_, control_NN B_NNP 5_CD ._. 8_CD %_NN ,_, and_CC
          control_NN C_NNP 5_CD ._. 1_CD %_NN ._. Inter-assay_NNP coefficients_NNS of_IN variation_NN
          were_VBD for_IN control_NN A_DT 7_CD ._. 9_CD %_NN ,_, control_NN B_NNP 6_CD ._. 5_CD %_NN ,_, control_NN C_NNP 6_CD ._. 0_CD %_NN ._.
          The_DT cortisol_NN response_NN was_VBD defined_VBN as_IN the_DT difference_NN
          between_IN the_DT basal_NN and_CC peak_NN cortisol_NN concentrations_NNS ._.
          Normal_NNP adrenal_NN function_NN was_VBD defined_VBN as_IN a_DT plasma_NN cortisol_NN
          level_NN (_( before_IN or_CC at_IN 30_CD or_CC 60_CD minutes_NNS after_IN the_DT injection_NN
          of_IN ACTH_NNP )_) above_IN 20_CD Î¼g_NN /_NN dl_NN ._. The_DT cases_NNS with_IN peak_NN cortisol_NN
          levels_NNS lower_JJR than_IN 20_CD Î¼g_NN /_NN dl_NN were_VBD considered_VBN to_TO be_VB AI_NNP [_NN 13_CD ,_,
          20_CD ,_, 21_CD ,_, 22_CD ]_NN ._. Occult_NNP AI_NNP was_VBD defined_VBN as_IN an_DT increase_NN in_IN
          cortisol_NN after_IN a_DT ACTH_NNP test_NN of_IN less_JJR than_IN 9_CD g_SYM /_NN dl_NN (_( a_DT
          cortisol_NN response_NN of_IN no_RB more_JJR than_IN 9_CD Î¼g_NN /_NN dl_NN )_) [_NN 17_CD ,_, 23_CD ,_,
          24_CD ]_NN ._.
          Community-acquired_NNP sepsis_NN had_VBD its_PRP$ onset_NN within_IN 72_CD
          hours_NNS of_IN the_DT patients_NNS '_POS admission_NN to_TO the_DT hospital_NN ,_, whereas_IN
          hospital-acquired_JJ sepsis_NN began_VBD 72_CD hours_NNS or_CC later_RB after_IN
          admission_NN ._. The_DT estimated_VBN prognosis_NN of_IN any_DT pre-existing_JJ
          underlying_VBG diseases_NNS had_VBD been_VBN classified_VBN according_VBG to_TO the_DT
          classification_NN of_IN McCabe_NNP and_CC Jackson_NNP [_NN 25_CD ]_NN ._.
          Observed_NNP initial_JJ findings_NNS that_WDT related_VBD to_TO disseminated_VBN
          intravas-cular_JJ coagulation_NN ,_, respiratory_JJ insufficiency_NN ,_,
          altered_VBD mental_JJ status_NN ,_, and_CC renal_JJ ,_, cardiac_JJ ,_, and_CC liver_NN
          failure_NN were_VBD noted_VBN [_NN 26_CD ,_, 27_CD ]_NN ._. The_DT severity_NN of_IN the_DT illness_NN
          was_VBD assessed_VBN with_IN the_DT Acute_NNP Physiology_NNP and_CC Chronic_NNP Health_NNP
          Evaluation_NNP II_NNP (_( APACHEII_NNP )_) scoring_VBG system_NN [_NN 28_CD ]_NN ._. The_DT
          Sequential_NNP Organ_NNP Failure_NN Assessment_NNP (_( SOFA_NNP )_) score_NN [_NN 29_CD ]_NN
          was_VBD added_VBN to_TO the_DT study_NN protocol_NN by_IN amendment_NN and_CC
          retrospectively_RB from_IN the_DT raw_JJ data_NN ._. Infections_NNP were_VBD
          diagnosed_VBN according_VBG to_TO clinical_JJ and_CC microbiological_JJ
          criteria_NNS ._. Blood_NNP samples_NNS for_IN cultures_NNS were_VBD obtained_VBN by_IN the_DT
          same_JJ investigator_NN (_( O_NNP Yildiz_NNP )_) and_CC inoculated_JJ into_IN a_DT
          standard_JJ culture_NN medium_NN (_( BACTEC_NNP 9240_CD )_) ._. Patients_NNS were_VBD
          evaluated_VBN at_IN enrollment_NN and_CC at_IN the_DT 24_CD th_NN hour_NN ,_, and_CC on_IN the_DT
          3_CD rd_NN ,_, 7_CD th_NN ,_, 10_CD th_NN ,_, 14_CD th_NN ,_, 21_CD st_NN ,_, and_CC 28_CD th_NN days_NNS ,_, and_CC followed_VBD
          for_IN 1_CD month_NN after_IN discharge_NN from_IN hospital_NN ._.
          Body_NN temperature_NN ,_, respiratory_JJ rate_NN ,_, heart_NN rate_NN ,_, blood_NN
          pressure_NN ,_, the_DT use_NN of_IN vasopressor_NN drugs_NNS ,_, urine_NN output_NN ,_,
          complete_JJ blood_NN counts_VBZ ,_, urinalysis_NNS with_IN microscopic_JJ
          examination_NN ,_, erythrocytes_NNS sedimentation_NN rate_NN ,_, blood_NN
          chemistry_NN ,_, prothrombin_NN time_NN ,_, partial_JJ thromboplastin_NN time_NN ,_,
          fibrinogen_NN ,_, fibrin_NN debranch-ing_JJ product_NN ,_, blood_NN gases_NNS ,_,
          electrocardiogram_NN ,_, and_CC chest_NN roentgenogram_NN were_VBD recorded_VBN
          for_IN each_DT patient_NN individually_RB ._.
        
        
          Study_NN endpoints_NNS
          The_DT primary_JJ endpoint_NN of_IN the_DT study_NN was_VBD 28_CD -_: day_NN mortality_NN
          from_IN all_DT causes_NNS ._. The_DT secondary_JJ endpoint_NN consisted_VBD of_IN
          adverse_JJ occurrences_NNS including_VBG possible_JJ complications_NNS of_IN
          drug_NN therapy_NN and_CC morbid_NN events_NNS such_JJ as_IN the_DT progression_NN of_IN
          initial_JJ infection_NN and_CC the_DT development_NN of_IN secondary_JJ
          infection_NN ._. Secondary_JJ infection_NN was_VBD defined_VBN as_IN the_DT
          identification_NN of_IN a_DT new_JJ site_NN of_IN infection_NN or_CC the_DT
          emergence_NN of_IN a_DT different_JJ organism_NN at_IN the_DT same_JJ site_NN ,_,
          generally_RB requiring_VBG a_DT change_NN in_IN antibiotic_JJ
          management_NN ._.
          All_DT medications_NNS given_VBN to_TO the_DT patients_NNS ,_, any_DT
          complications_NNS ,_, the_DT duration_NN of_IN hospitalization_NN ,_, the_DT
          mortality_NN rate_NN ,_, and_CC the_DT causes_NNS of_IN death_NN were_VBD recorded_VBN and_CC
          compared_VBN between_IN the_DT groups_NNS ._. We_PRP also_RB compared_VBD average_JJ
          values_NNS of_IN basal_NN cortisol_NN ,_, peak_NN cortisol_NN and_CC cortisol_NN
          responses_NNS to_TO ACTH_NNP between_IN survivors_NNS and_CC non-survivors_JJ on_IN
          the_DT first_JJ day_NN ._. Moreover_RB ,_, basal_NN cortisol_NN levels_NNS on_IN the_DT 1_CD st_NN
          and_CC 14_CD th_NN days_NNS were_VBD compared_VBN in_IN patients_NNS who_WP recovered_VBD in_IN
          each_DT group_NN ._.
        
        
          Statistical_NNP analysis_NN
          Student_NNP 's_POS 
          t_NN -_: test_NN and_CC the_DT Mann-_NNP Whitney_NNP 
          U_NNP multivariate_NN analysis_NN test_NN were_VBD
          used_VBN for_IN continuous_JJ variables_NNS ,_, Ï_NN 2_CD and_CC Fisher_NNP 's_POS Ï_NN 2_CD tests_NNS
          were_VBD used_VBN for_IN proportions_NNS ,_, and_CC logistic_JJ regression_NN was_VBD
          used_VBN for_IN effects_NNS of_IN factors_NNS on_IN mortality_NN ._. Values_NNP are_VBP
          expressed_VBN as_IN means_VBZ Â±_NN SD_NNP ,_, odds_NNS ratio_NN (_( OR_NNP )_) and_CC 95_CD %_NN
          confidence_NN interval_NN (_( CI_NNP )_) or_CC proportion_NN ._.
        
      
      
        Results_NNS
        
          Description_NNP of_IN study_NN population_NN
          Forty_CD patients_NNS with_IN sepsis_NN ,_, severe_JJ sepsis_NN and_CC septic_JJ
          shock_NN were_VBD included_VBN in_IN this_DT study_NN ._. The_DT mean_JJ age_NN of_IN
          patients_NNS was_VBD 56_CD ._. 5_LS Â±_NN 16_CD ._. 4_LS years_NNS in_IN the_DT standard_JJ therapy_NN
          group_NN and_CC 57_CD ._. 8_CD Â±_NN 17_CD ._. 7_CD years_NNS in_IN the_DT steroid_NN therapy_NN group_NN ._.
          There_EX was_VBD no_DT significant_JJ difference_NN in_IN demographic_JJ
          characteristics_NNS ,_, the_DT severity_NN of_IN underlying_VBG diseases_NNS ,_, the_DT
          APACHE_NNP II_NNP and_CC SOFA_NNP scores_NNS ,_, the_DT median_JJ time_NN to_TO hospital_NN
          and_CC median_JJ time_NN to_TO death_NN ,_, the_DT acquisition_NN of_IN infection_NN ,_,
          and_CC the_DT sepsis_NN categories_NNS between_IN the_DT groups_NNS (_( Table_NNP
          2_LS )_) ._.
        
        
          The_DT 28_CD -_: day_NN mortality_NN
          There_EX were_VBD eight_CD deaths_NNS (_( 40_CD %_NN )_) in_IN the_DT steroid_NN therapy_NN
          group_NN and_CC 12_CD (_( 60_CD %_NN )_) deaths_NNS in_IN the_DT standard_JJ therapy_NN group_NN (_(
          
          P_NN =_SYM 0_CD ._. 343_CD )_) ._. The_DT mortality_NN rate_NN in_IN
          the_DT patients_NNS with_IN hospital-acquired_JJ sepsis_NN was_VBD higher_JJR
          than_IN that_DT in_IN the_DT patients_NNS with_IN community-acquired_JJ sepsis_NN
          in_IN both_DT groups_NNS ,_, but_CC this_DT difference_NN was_VBD not_RB statistically_RB
          significant_JJ ._. The_DT relationship_NN between_IN mortality_NN and_CC age_NN ,_,
          the_DT presence_NN of_IN an_DT underlying_VBG disease_NN ,_, vasopressor_NN and_CC
          steroid_NN therapy_NN ,_, and_CC APACHE_NNP II_NNP and_CC SOFA_NNP scores_NNS was_VBD
          assessed_VBN ._. Age_NNP ,_, the_DT presence_NN of_IN an_DT underlying_VBG disease_NN ,_,
          steroid_NN therapy_NN ,_, basal_NN plasma_NN cortisol_NN levels_NNS ,_, and_CC
          cortisol_NN response_NN to_TO ACTH_NNP below_IN 9_CD g_SYM /_NN dl_NN were_VBD not_RB
          associated_VBN with_IN mortality_NN ._. Although_IN a_DT univariate_NN analysis_NN
          found_VBD vasopressor_NN therapy_NN (_( OR_NNP 4_CD ._. 64_CD ,_, 95_CD %_NN CI_NNP 1_CD ._. 02_CD -_: 21_CD ._. 00_CD )_) ,_,
          APACHE_NNP II_NNP (_( OR_NNP 1_CD ._. 18_CD ,_, 95_CD %_NN CI_NNP 1_CD ._. 04_CD -_: 1_CD ._. 34_CD )_) and_CC maximum_NN SOFA_NNP
          (_( OR_NNP 1_CD ._. 63_CD ,_, 95_CD %_NN CI_NNP 1_CD ._. 23_CD -_: 2_CD ._. 16_CD )_) to_TO be_VB effective_JJ on_IN mortality_NN ,_,
          only_RB the_DT SOFA_NNP score_NN was_VBD found_VBN related_VBN to_TO mortality_NN ,_,
          independently_RB of_IN other_JJ factors_NNS (_( OR_NNP 2_CD ._. 09_CD ,_, 95_CD %_NN CI_NNP
          1_CD ._. 01_CD -_: 4_CD ._. 30_CD )_) in_IN a_DT multivariate_NN analysis_NN (_( Fig_NNP ._. 1_LS and_CC Table_NNP
          3_LS )_) ._.
        
        
          Variations_NNP of_IN treatment_NN effects_NNS on_IN the_DT 28_CD -_: day_NN
          mortality_NN among_IN subgroups_NNS
          The_DT mortality_NN rates_NNS among_IN patients_NNS with_IN a_DT cortisol_NN
          level_NN over_IN 60_CD Î¼g_NN /_NN dl_NN were_VBD 29_CD %_NN (_( 2_CD of_IN 7_CD )_) in_IN the_DT steroid_NN
          therapy_NN group_NN and_CC 78_CD %_NN (_( 7_CD of_IN 9_CD )_) in_IN the_DT standard_JJ therapy_NN
          group_NN (_( Ï_NN 2_CD =_SYM 3_CD ._. 874_CD ,_, 
          P_NN =_SYM 0_CD ._. 126_CD )_) ._. Although_IN there_EX was_VBD an_DT
          increase_NN in_IN the_DT level_NN of_IN basal_NN cortisol_NN in_IN patients_NNS with_IN
          sepsis_NN ,_, 14_CD of_IN 40_CD patients_NNS (_( 35_CD %_NN )_) had_VBD occult_NN AI_NNP ._. The_DT
          mortality_NN rates_NNS in_IN patients_NNS with_IN occult_NN AI_NNP were_VBD 40_CD %_NN (_( 2_CD of_IN
          5_LS )_) in_IN the_DT steroid_NN therapy_NN group_NN and_CC 55_CD ._. 6_CD %_NN (_( 5_CD of_IN 9_CD )_) in_IN the_DT
          standard_JJ therapy_NN group_NN ,_, respectively_RB (_( Ï_NN 2_CD =_SYM 0_CD ._. 311_CD ,_, 
          P_NN =_SYM 1_LS )_) ._. Only_RB one_CD patient_NN had_VBD both_DT
          basal_NN and_CC peak_NN cortisol_NN levels_NNS lower_JJR than_IN 20_CD g_SYM /_NN dl_NN ;_: this_DT
          patient_NN was_VBD in_IN the_DT standard_JJ therapy_NN group_NN and_CC died_VBD on_IN the_DT
          7_CD th_NN day_NN of_IN treatment_NN ._. This_DT case_NN was_VBD accepted_VBN as_IN adrenal_NN
          failure_NN ._. A_DT comparison_NN of_IN mortality_NN rates_NNS for_IN basal_NN
          cortisol_NN and_CC cortisol_NN responses_NNS to_TO ACTH_NNP in_IN both_DT groups_NNS is_VBZ
          shown_VBN in_IN Figure_NN 1_CD ._. The_DT median_JJ time_NN to_TO death_NN was_VBD 5_CD days_NNS
          (_( 95_CD %_NN CI_NNP 2_CD ._. 55_CD -_: 8_CD ._. 20_CD )_) in_IN the_DT steroid_NN therapy_NN group_NN and_CC 5_CD ._. 5_CD
          days_NNS (_( 95_CD %_NN CI_NNP 2_CD ._. 19_CD -_: 13_CD )_) in_IN the_DT standard_JJ therapy_NN group_NN (_( 
          P_NN =_SYM 0_CD ._. 496_CD )_) ._. The_DT reason_NN for_IN death_NN in_IN
          all_DT patients_NNS was_VBD attributed_VBN to_TO sepsis_NN ._. The_DT median_JJ stay_NN in_IN
          hospital_NN was_VBD 14_CD days_NNS (_( 95_CD %_NN CI_NNP 11_CD ._. 09_CD -_: 20_CD ._. 08_CD )_) in_IN the_DT steroid_NN
          therapy_NN group_NN and_CC 13_CD days_NNS (_( 95_CD %_NN CI_NNP 10_CD ._. 13_CD -_: 16_CD ._. 37_CD )_) in_IN the_DT
          standard_JJ therapy_NN group_NN (_( 
          P_NN =_SYM 0_CD ._. 406_CD )_) ._.
        
        
          Sepsis-related_NNP organ_NN dysfunction_NN
          Organ_NNP dysfunction_NN and_CC failure_NN rates_NNS of_IN the_DT patients_NNS on_IN
          admission_NN were_VBD 40_CD %_NN and_CC 45_CD %_NN in_IN the_DT steroid_NN therapy_NN and_CC the_DT
          standard_JJ therapy_NN groups_NNS ,_, respectively_RB (_( Table_NNP 4_LS )_) ._. No_DT
          statistically_RB significant_JJ difference_NN was_VBD found_VBN between_IN
          the_DT changes_NNS in_IN the_DT percentage_NN of_IN SOFA_NNP scores_NNS of_IN the_DT
          steroid_NN therapy_NN group_NN (_( 43_CD ._. 1_LS Â±_NN 26_CD ._. 5_LS %_NN )_) and_CC the_DT standard_JJ
          therapy_NN group_NN (_( 45_CD ._. 4_LS Â±_NN 12_CD ._. 7_CD %_NN )_) in_IN survivors_NNS (_( 
          P_NN =_SYM 0_CD ._. 624_CD )_) ._.
        
        
          Cortisol_NNP levels_NNS and_CC cortisol_NN responses_NNS to_TO
          ACTH_NNP
          Basal_NNP and_CC peak_NN cortisol_NN levels_NNS and_CC cortisol_NN responses_NNS
          to_TO ACTH_NNP in_IN the_DT steroid_NN therapy_NN group_NN were_VBD not_RB
          significantly_RB different_JJ from_IN those_DT in_IN the_DT standard_JJ
          therapy_NN group_NN (_( Table_NNP 5_LS )_) ._. The_DT average_JJ values_NNS of_IN basal_NN
          cortisol_NN ,_, peak_NN cortisol_NN and_CC cortisol_NN responses_NNS to_TO ACTH_NNP in_IN
          survivors_NNS and_CC non-survivors_JJ in_IN both_DT groups_NNS for_IN the_DT first_JJ
          day_NN are_VBP shown_VBN in_IN Table_NNP 3_CD ._. There_EX was_VBD no_DT significant_JJ
          difference_NN between_IN the_DT values_NNS for_IN survivors_NNS and_CC
          non-survivors_JJ ._. The_DT mean_JJ basal_NN cortisol_NN level_NN was_VBD 47_CD ._. 6_CD Â±_NN
          26_CD ._. 9_CD g_SYM /_NN dl_NN on_IN the_DT first_JJ day_NN in_IN all_DT survivors_NNS and_CC 17_CD ._. 2_LS Â±_NN
          8_CD ._. 6_CD g_SYM /_NN dl_NN on_IN the_DT 14_CD th_NN day_NN in_IN patients_NNS who_WP recovered_VBD (_( 
          P_NN =_SYM 0_CD ._. 0003_CD )_) ._. In_IN the_DT steroid_NN therapy_NN
          group_NN ,_, the_DT mean_JJ basal_NN cortisol_NN level_NN was_VBD 52_CD ._. 5_LS Â±_NN 30_CD ._. 5_LS g_SYM /_NN dl_NN
          on_IN the_DT first_JJ day_NN and_CC 17_CD ._. 6_CD Â±_NN 10_CD ._. 3_LS g_SYM /_NN dl_NN on_IN the_DT 14_CD th_NN day_NN (_( 
          P_NN =_SYM 0_CD ._. 003_CD )_) ._. In_IN the_DT standard_JJ therapy_NN
          group_NN ,_, the_DT mean_JJ basal_NN cortisol_NN level_NN was_VBD 40_CD ._. 3_LS Â±_NN 19_CD ._. 9_CD g_SYM /_NN dl_NN
          on_IN the_DT first_JJ day_NN and_CC 16_CD ._. 4_LS Â±_NN 4_CD ._. 6_CD g_SYM /_NN dl_NN on_IN the_DT 14_CD th_NN day_NN (_( 
          P_NN =_SYM 0_CD ._. 028_CD )_) (_( Table_NNP 6_CD )_) ._.
        
        
          Adverse_JJ events_NNS
          There_EX were_VBD no_DT adverse_JJ effects_NNS due_JJ to_TO steroid_NN therapy_NN ._.
          Only_RB one_CD patient_NN ,_, in_IN the_DT standard_JJ therapy_NN group_NN ,_, had_VBD a_DT
          secondary_JJ infection_NN ._.
        
      
      
        Discussion_NNP
        Sepsis_NNP is_VBZ a_DT severe_JJ and_CC life-threatening_JJ disease_NN ._. Septic_NNP
        shock_NN is_VBZ associated_VBN with_IN a_DT mortality_NN rate_NN of_IN more_JJR than_IN 50_CD %_NN ._.
        Despite_IN improvements_NNS in_IN the_DT overall_JJ management_NN of_IN such_JJ
        patients_NNS ,_, including_VBG intensive_JJ fluid_JJ resuscitation_NN ,_,
        broad-spectrum_JJ antibiotic_JJ therapy_NN ,_, and_CC life-support_JJ
        devices_NNS ,_, mortality_NN rates_NNS have_VBP not_RB improved_VBN during_IN the_DT past_JJ
        decade_NN [_NN 4_CD ]_NN ._. In_IN this_DT randomized_JJ ,_, double-blind_JJ study_NN of_IN the_DT
        physiological_JJ dose_NN of_IN intravenous_JJ prednisolone_NN or_CC placebo_NN
        in_IN the_DT treatment_NN of_IN sepsis_NN ,_, we_PRP observed_VBD an_DT important_JJ
        difference_NN in_IN mortality_NN rates_NNS between_IN both_DT groups_NNS ._. The_DT
        mortality_NN rates_NNS were_VBD 40_CD %_NN in_IN the_DT steroid_NN therapy_NN group_NN and_CC
        60_CD %_NN in_IN the_DT standard_JJ treatment_NN group_NN ._. There_EX was_VBD a_DT trend_NN
        towards_IN a_DT decrease_NN in_IN the_DT mortality_NN rate_NN of_IN the_DT patients_NNS
        with_IN sepsis_NN who_WP received_VBD physiological-dose_JJ steroid_NN
        therapy_NN ._. However_RB ,_, the_DT differences_NNS were_VBD not_RB statisti-Î¼_JJ cally_RB
        significant_JJ (_( 
        P_NN =_SYM 0_CD ._. 343_CD )_) ._. Several_JJ factors_NNS were_VBD
        suspected_VBN to_TO be_VB associated_VBN with_IN mortality_NN in_IN sepsis_NN [_NN 30_CD ,_,
        31_CD ]_NN ._. Annane_NNP 
        et_CC al_NN ._. [_NN 17_CD ]_NN reported_VBD that_IN SOFA_NNP
        score_NN ,_, high_JJ plasma_NN cortisol_NN levels_NNS and_CC weak_JJ response_NN of_IN
        cortisol_NN to_TO ACTH_NNP were_VBD also_RB associated_VBN with_IN mortality_NN ._.
        However_RB ,_, we_PRP found_VBD that_IN only_RB SOFA_NNP score_NN was_VBD related_VBN to_TO
        mortality_NN ,_, independently_RB of_IN other_JJ factors_NNS (_( OR_NNP 2_CD ._. 07_CD ,_, 95_CD %_NN CI_NNP
        1_CD ._. 02_CD -_: 4_CD ._. 22_CD )_) in_IN the_DT multivariate_NN analysis_NN ._.
        Briegel_NNP 
        et_CC al_NN ._. [_NN 19_CD ]_NN showed_VBD that_IN stress_NN doses_NNS
        of_IN hydrocorti-sone_JJ reduce_VB the_DT time_NN for_IN the_DT reversal_NN of_IN
        shock_NN ,_, the_DT number_NN of_IN organ_NN system_NN failures_NNS ,_, and_CC the_DT length_NN
        of_IN mechanical_JJ ventilation_NN in_IN patients_NNS with_IN septic_JJ shock_NN ._.
        This_DT finding_VBG underlines_NNS the_DT fact_NN that_IN an_DT impaired_VBN
        adrenocortical_JJ function_NN contributes_VBZ to_TO vascular_NN
        hyporesponsiveness_NNS in_IN septic_JJ shock_NN ._. In_IN contrast_NN to_TO other_JJ
        studies_NNS ,_, our_PRP$ study_NN was_VBD performed_VBN in_IN patients_NNS with_IN sepsis_NN ,_,
        severe_JJ sepsis_NN and_CC septic_JJ shock_NN with_IN the_DT use_NN of_IN
        physiological-dose_JJ prednisolone_NN with_IN or_CC without_IN vasopressor_NN
        support_NN ._. Because_IN the_DT administration_NN of_IN prednisolone_NN does_VBZ
        not_RB affect_VB the_DT circadian_NN adrenocortical_JJ patterns_NNS and_CC the_DT
        results_NNS of_IN an_DT ACTH_NNP stimulation_NN test_NN in_IN adults_NNS ,_, we_PRP preferred_VBN
        to_TO use_VB this_DT drug_NN [_NN 32_CD ]_NN ._. In_IN this_DT study_NN we_PRP did_VBD not_RB completely_RB
        evaluate_VB the_DT effect_NN of_IN the_DT steroid_NN on_IN patients_NNS with_IN
        vasopressor-dependent_JJ septic_JJ shock_NN ._. However_RB ,_, in_IN a_DT few_JJ
        patients_NNS ,_, a_DT physiological_JJ dose_NN of_IN prednisolone_NN reduces_VBZ the_DT
        time_NN for_IN the_DT reversal_NN of_IN shock_NN as_IN defined_VBN by_IN the_DT cessation_NN
        of_IN vasopressor_NN therapy_NN ._.
        It_PRP is_VBZ known_VBN that_IN the_DT plasma_NN cortisol_NN level_NN increases_NNS in_IN
        critical_JJ illnesses_NNS and_CC that_DT basal_NN cortisol_NN levels_NNS have_VBP a_DT
        positive_JJ correlation_NN with_IN severity_NN of_IN illness_NN and_CC
        prognosis_NN ._. However_RB ,_, some_DT investigators_NNS [_NN 16_CD ,_, 23_CD ,_, 33_CD ,_, 34_CD ,_,
        35_CD ]_NN showed_VBD that_IN patients_NNS with_IN sepsis_NN and_CC high_JJ baseline_NN
        cortisol_NN levels_NNS had_VBD a_DT lower_JJR cortisol_NN response_NN to_TO the_DT ACTH_NNP
        stimulation_NN test_NN ._. Our_PRP$ entire_JJ study_NN group_NN had_VBD higher_JJR mean_NN
        random_JJ basal_NN and_CC stimulated_VBN cortisol_NN levels_NNS than_IN those_DT seen_VBN
        in_IN outpatients_NNS ._. The_DT difference_NN between_IN the_DT basal_NN cortisol_NN
        levels_NNS on_IN the_DT 1_CD st_NN and_CC 14_CD th_NN days_NNS in_IN patients_NNS who_WP recovered_VBD
        was_VBD statistically_RB significant_JJ (_( 
        P_NN <_NN 0_CD ._. 0001_CD )_) (_( Table_NNP 5_LS )_) ._. We_PRP have_VBP
        also_RB shown_VBN that_DT basal_NN cortisol_NN levels_NNS correlate_VBP with_IN the_DT
        severity_NN of_IN the_DT illness_NN ,_, and_CC that_IN very_RB high_JJ corti-sol_JJ
        levels_NNS signify_VB a_DT poor_JJ prognosis_NN in_IN the_DT standard_JJ therapy_NN
        group_NN (_( Fig_NNP ._. 1_LS )_) ._.
        Clinically_NNP significant_JJ AI_NNP is_VBZ unusual_JJ in_IN outpatients_NNS ._. The_DT
        studies_NNS of_IN adrenal_NN function_NN in_IN critically_RB ill_JJ patients_NNS
        report_VBP conflicting_JJ incidences_NNS of_IN AI_NNP ranging_VBG from_IN 0_CD %_NN to_TO 28_CD %_NN
        [_NN 35_CD ,_, 36_CD ,_, 37_CD ]_NN ._. Our_PRP$ results_NNS show_VBP a_DT low_JJ incidence_NN of_IN AI_NNP in_IN
        septic_JJ patients_NNS ._. One_CD of_IN our_PRP$ 40_CD patients_NNS had_VBD abnormal_JJ basal_NN
        and_CC peak_NN cortisol_NN levels_NNS (_( less_JJR than_IN 20_CD g_SYM /_NN dl_NN )_) and_CC died_VBD ._. This_DT
        condition_NN was_VBD evaluated_VBN as_IN AI_NNP ._. In_IN the_DT advancing_VBG process_NN
        from_IN sepsis_NN to_TO septic_JJ shock_NN ,_, we_PRP concluded_VBD that_IN AI_NNP was_VBD not_RB
        so_RB frequent_JJ as_IN supposed_VBN ._.
        In_IN recent_JJ years_NNS ,_, several_JJ authors_NNS have_VBP proposed_VBN a_DT
        syndrome_NN of_IN occult_NN AI_NNP in_IN septic_JJ shock_NN in_IN the_DT presence_NN of_IN
        normal_JJ or_CC even_RB elevated_VBD serum_NN cortisol_NN concentrations_NNS ._.
        Annane_NNP 
        et_CC al_NN ._. [_NN 17_CD ]_NN reported_VBD that_IN 50_CD %_NN of_IN
        patients_NNS with_IN severe_JJ sepsis_NN had_VBD occult_NN AI_NNP ._. In_IN the_DT present_JJ
        study_NN ,_, 14_CD (_( 35_CD %_NN )_) of_IN the_DT 40_CD patients_NNS had_VBD a_DT subnormal_NN cortisol_NN
        response_NN (_( occult_NN AI_NNP )_) ._. Five_CD patients_NNS in_IN the_DT steroid_NN
        treatment_NN group_NN had_VBD an_DT inadequate_JJ cortisol_NN response_NN ;_: two_CD of_IN
        them_PRP died_VBD ._. However_RB ,_, five_CD of_IN nine_CD patients_NNS in_IN the_DT standard_JJ
        treatment_NN group_NN who_WP showed_VBD inadequate_JJ cortisol_NN response_NN
        died_VBD ._. No_DT statistical_JJ differences_NNS were_VBD observed_VBN in_IN mortality_NN
        rates_NNS between_IN the_DT patients_NNS who_WP had_VBD occult_NN AI_NNP (_( Ï_NN 2_CD =_SYM 0_CD ._. 311_CD ,_, 
        P_NN =_SYM 1_LS )_) (_( Fig_NNP ._. 1_LS )_) ._.
        In_IN conclusion_NN ,_, a_DT physiological_JJ dose_NN of_IN intravenous_JJ
        pred-nisolone_JJ had_VBD a_DT tendency_NN towards_IN a_DT decrease_NN in_IN
        mortality_NN in_IN the_DT patients_NNS with_IN sepsis_NN ,_, but_CC the_DT difference_NN
        between_IN the_DT two_CD groups_NNS was_VBD not_RB significant_JJ ._. Because_IN our_PRP$
        study_NN had_VBD a_DT small_JJ sample_NN size_NN and_CC showed_VBD heterogeneity_NN in_IN
        population_NN in_IN terms_NNS of_IN clinical_JJ severity_NN ,_, treatment_NN with_IN
        physiological-dose_JJ steroid_NN in_IN sepsis_NN should_MD be_VB evaluated_VBN in_IN
        a_DT larger_JJR group_NN of_IN patients_NNS ._.
      
      
        Key_JJ messages_NNS
        Â·_NN There_EX was_VBD an_DT increase_NN in_IN the_DT level_NN of_IN basal_NN cortisol_NN
        in_IN patients_NNS with_IN sepsis_NN ._.
        Â·_NN In_IN the_DT advancing_VBG process_NN from_IN sepsis_NN to_TO septic_JJ shock_NN ,_,
        adrenal_NN insufficiency_NN was_VBD not_RB so_RB frequent_JJ as_IN supposed_VBN ._.
        Â·_NN Sepsis_NNP can_MD cause_VB occult_NN adrenal_NN insufficiency_NN in_IN the_DT
        presence_NN of_IN normal_JJ or_CC even_RB elevated_VBD serum_NN cortisol_NN
        concentrations_NNS ._.
        Â·_NN Physiological-dose_NNP prednisolone_NN therapy_NN had_VBD a_DT tendency_NN
        towards_IN a_DT decrease_NN in_IN mortality_NN in_IN the_DT patients_NNS with_IN
        sepsis_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        AI_NNP =_SYM adrenal_NN insufficiency_NN ;_: APACHE_NNP =_SYM Acute_NNP Physiology_NNP
        and_CC Chronic_NNP Health_NNP Evaluation_NNP ;_: ACTH_NNP =_SYM corticotropin_NN ;_: CI_NNP =_SYM
        confidence_NN interval_NN ;_: OR_NNP =_SYM odds_NNS ratio_NN ;_: SOFA_NNP =_SYM Sequential_NNP
        Organ_NNP Failure_NN Assessment_NNP ._.
      
    
  
